Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Immune Cell Traits and Aortic Dissection: A Mendelian Randomisation Study
Author(s): Tian-le Li , Mao-long Fu , Li-hong Wang , et al Added: 9 months ago

Electrophysiology & Arrhythmia

Inherited and Congenital Cardiac Conditions
Immune Cell Traits and Heart Failure: A Mendelian Randomisation Study
Author(s): Wei Gao , Hui Wang , Jian-long Wang , et al Added: 2 months ago

Demographic

Heart Failure
Erratum: Causal Characteristics of Immune Cells
Author(s): Tian-le Li , Mao-long Fu , Li-hong Wang , et al Added: 8 months ago
ACC 2025: The CardiAMP-HF Trial
Author(s): Amish Raval Added: 9 months ago
ACC 2025 - Principal results from autologous cell therapy in patients with heart failure with reduced ejection fraction (HFrEF) show favourable safety outcomes, however, the study did not meet its primary efficacy outcome using 6 minute walking rests as 3rd F-S tier.Dr Amish Raval (UW Health University Hospital Interventional Cardiology Clinic, WI, US) joins us onsite at ACC to discuss the… View more

Heart Failure
Author(s): Fatin Fazrina Roslan , Yuexin Yu , Nurul Ain Nasim Mohd Yusof , et al Added: 1 year ago

Anticoagulation
MicroRNAs for Cardiac Regeneration
Author(s): Camilla Olianti , Mauro Giacca Added: 3 months ago

Heart Failure

Prevention & Chronic Conditions
Research Area(s) / Expertise:

Expertise

Digital Health
Job title: Senior Medical Assessor
Job title: Director of Regulatory Affairs
The Index Valve Matters: Optimal Index TAVI for Patients Lifetime Management
Author(s): Michael Joner Added: 3 weeks ago
In this interview, Prof Michael Joner (German Heart Centre, Munich, DE) discusses the specific needs and treatment considerations when managing low and intermediate risk TAVI patients. He also highlights the increasing need to consider future interventions when selecting the index valve.Prof Joner details the Navitor TAVI system resheathable design with intra-annular function, large-cell frame… View more

Intervention
ESC 25: The SEMA-VR CardioLink-15 Trial
Author(s): Subodh Verma Added: 4 months ago
ESC Congress 2025 - The SEMA-VR CardioLink-15 trial revealed that semaglutide may enhance endogenous progenitor cell-mediated vasculogenic repair processes.Dr Subodh Verma (University of Toronto, Toronto, CA) joins us to discuss the findings from the SEMA-VR CardioLink-15 trial. The study compared usual care with semaglutide, GLP-1RA for six months in 46 patients with either type 2 diabetes… View more

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions